ANZCTR search results

Generalized Anxiety Disorder (GAD) is a disabling disorder characterized by the central defining feature of pervasive, excessive and uncontrollable worry. Although the traditional Cognitive Behavioural Therapy (CBT) has been found to be effective for GAD patients, a significant proportion of these patients fail to achieve high end-state functioning. Recent research evidence have found GAD to be associated with a person's intolerance of uncertainty, unhelpful meta-cognitions, and deficits in emotional regulation. The current study thus aims to investigate the efficacy of an enhanced CBT treatment that teaches GAD patients skills in managing emotions, uncertainty and unhelpful meta-cognitions, in addition to the usual CBT skills. It is hypothesized that GAD-related symptoms in the patients will improve with the enhanced CBT treatment and the change of symptoms will be related to change in scores (baseline to post-treatment) in one or more of the aforesaid factors (i.e. emotion regulation, meta-cognitions and/or intolerance of uncertainty).

Breathlessness continues to be a major clinical problem for many people with advanced progressive illnesses such as chronic obstructive pulmonary disease, end-stage cardiac failure, and cancer, even when they are receiving the best treatment for their underlying disease. There are phase II/III data and one meta-analysis which support the use of morphine in this setting, but further good phase III data are needed in order to that this is a well tolerated and effective intervention suitable for a broad range of people with refractory breathlessness. It is also important to establish that the overall net benefit outweighs any toxicity encountered. Further, a particular concern to many clinicians is the theoretical risk that opioids may cause respiratory depression. In steady state, at the relatively low regular doses proposed, there are no data to support this concern, but this study will specifically address this question through careful collection of non-invasive measures of respiratory function regularly throughout the study including end-tidal carbon dioxide at the beginning and the end of the study. Objectives: Among participants with refractory breathlessness: 1) To compare the efficacy for relieving the sensation of dyspnoea, level of function, safety and quality of life (QOL) of opioids (sustained release morphine) with placebo; 2) To identify clinical and pharmacogenomic parameters that predict which individuals will achieve the greatest benefit from the intervention and establish any blinded participant preference. Secondary objectives focus of the impact of the intervention on improving quality of life, adverse effects, function, use of breakthrough opioids and clinical predictors of benefit. Study design: This is a phase III, multi-site, randomised double-blind parallel arm fixed dose controlled trial studying treatment approaches for the palliative relief of breathlessness in participants with refractory dyspnoea. Participants will be randomised to fixed dose identical-appearing sustained release morphine (20 mg every 24 hours), or placebo for one week. The intervention period will run for 7 days; participants will receive study interventions at target doses and blinded therapy for constipation with each active arm together with identical appearing placebo for constipation for the placebo arm.

This registry will enhance the national medical research effort for improved patient outcomes in Australia through improved diagnosis, reporting and management of NETs by collaboration among specialist oncologists, cancer registries and trialists at state and national levels.

Many patients with lung disease who use inhalers (puffers) are unable to generate enough strength when breathing in through their puffers. Often, they breathe too hard with some puffers. This breathing strength is generally known as the Inspiratory Flow Rate (IFR). Inappropriate IFR leads to sub-optimal use of puffers, compromising the effectiveness of patients' treatment. This study aims to know how common this problem is and to test the idea that training patients to achieve appropriate IFR leads to better outcomes. These outcomes include improved breathing, better quality of life, and reduced emergency department visits, as well as shorter hospital stays.

The primary purpose of this study is to determine which patients who suffer from cervical dystonia respond the best to botulinum toxin treatment.

People with type 2 diabetes have a higher risk of diseases affecting large blood vessels, such as heart attack, stroke, and blockage to blood flow in the leg, as well as diseases of small blood vessels affecting the eyes, kidneys and nerves. One of the early markers of blood vessel problems is poor function of the blood vessel lining, called the endothelium. Dysfunction of the endothelium predicts cardiovascular events. Exercise is important for management of type 2 diabetes. Currently, people with type 2 diabetes are encouraged to perform moderate intensity aerobic exercise, and if there are no contraindications, muscle-strengthening (resistance) exercise. In terms of the effect on endothelial function, the optimal exercise prescription is not known. This study will examine the effect of resistance training alone and aerobic training alone on endothelial function in people with type 2 diabetes who were previously insufficiently active. By doing this study, we will discover more about how the different types of exercise influence blood vessel function in people with type 2 diabetes.

The purpose of the study is to investigate the effects of thin water in patients who have been prescribed thickened fluids. The hypothesis is that there will be no ill effects and that quality of life will be improved as aresult of the provision of thin water to patients with dysphagia who have been prescribed thickened fluids.

The primary purpose of this study is to compare the efficacy of PainEase and Angel for reducing pain associated with intravenous cannulation in children. The study hypothesis is that application of PainEase will reduce pain associated with drip insertion.We would be comparing PainEase with the current standard treatment of use of Angel for reducing pain associated with drip insertion.

Objectives: A) To determine a population estimate of the efficacy of Mehtylphenidate in alleviating fatigue in patients with advanced cancer. B) To provide process evaluation on the feasibility of Single Patient Trials as a routine means of conducting clinical trials in palliative care. C) To develop, employ and recommend appropriate statistical techniques for the analysis of Single Patient Trial data derived from patients with advanced cancer; specifically, to develop and evaluate a method that estimates the effect of patient deterioration over the conduct of clinical trials and, where appropriate, provides a means of adjusting for illness progression.